JP2016520583A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016520583A5 JP2016520583A5 JP2016512227A JP2016512227A JP2016520583A5 JP 2016520583 A5 JP2016520583 A5 JP 2016520583A5 JP 2016512227 A JP2016512227 A JP 2016512227A JP 2016512227 A JP2016512227 A JP 2016512227A JP 2016520583 A5 JP2016520583 A5 JP 2016520583A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- pappalysin
- stanniocalcin
- agent
- interacting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201370259 | 2013-05-10 | ||
| DKPA201370259 | 2013-05-10 | ||
| PCT/DK2014/050131 WO2014180485A2 (en) | 2013-05-10 | 2014-05-12 | Pappalysin regulator |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016520583A JP2016520583A (ja) | 2016-07-14 |
| JP2016520583A5 true JP2016520583A5 (enExample) | 2017-06-15 |
Family
ID=50943008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016512227A Pending JP2016520583A (ja) | 2013-05-10 | 2014-05-12 | パッパリシンレギュレーター |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20160151405A1 (enExample) |
| EP (1) | EP2994158A2 (enExample) |
| JP (1) | JP2016520583A (enExample) |
| CN (1) | CN105263510A (enExample) |
| CA (1) | CA2911933A1 (enExample) |
| EA (1) | EA201591894A1 (enExample) |
| HK (1) | HK1215929A1 (enExample) |
| MX (1) | MX2015015519A (enExample) |
| WO (1) | WO2014180485A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3941523A4 (en) | 2019-03-22 | 2022-12-28 | Mayo Foundation for Medical Education and Research | MATERIALS AND METHODS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE |
| WO2022004054A1 (ja) * | 2020-06-30 | 2022-01-06 | 国立大学法人東北大学 | Ｓｔａｔ３のリン酸化抑制剤、自己免疫疾患及びコロナウイルス感染症の予防又は治療剤 |
| WO2022150409A1 (en) * | 2021-01-05 | 2022-07-14 | Mayo Foundation For Medical Education And Research | Treatments for intraocular pressure related disorders |
| US20240301503A1 (en) * | 2021-06-22 | 2024-09-12 | Dong-A University Research Foundation For Industry-Academy Cooperation | Novel biomarker for diagnosing and predicting metastasis or prognosis of various cancers, and use |
| WO2024042220A1 (en) * | 2022-08-25 | 2024-02-29 | Aarhus Universitet | Modulators of papp-a activity |
| EP4619023A1 (en) | 2022-11-15 | 2025-09-24 | Calico Life Sciences LLC | Anti-papp-a antibodies and methods of use thereof |
| WO2026008015A1 (en) * | 2024-07-05 | 2026-01-08 | The University Of Hong Kong | Stanniocalcin 2 (stc2) and derivatives as anti-diabetic agents |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5994103A (en) * | 1995-06-02 | 1999-11-30 | Human Genome Science, Inc. | Human stanniocalcin-alpha |
| CA2387685A1 (en) * | 1999-10-27 | 2001-05-03 | Human Genome Sciences, Inc. | Stanniocalcin proteins and nucleic acids and methods based thereon |
| JP2003525595A (ja) | 1999-11-01 | 2003-09-02 | キュラゲン コーポレイション | 脈管形成に含まれる差動発現遺伝子、それにコードされるポリペプチド、及びそれを用いた方法 |
| US20050009136A1 (en) | 2003-02-19 | 2005-01-13 | Dyax Corporation | PAPP-A ligands |
| WO2008101118A2 (en) | 2007-02-14 | 2008-08-21 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | A gene expression signature identifying pro-angiogenic genes in ovarian tumor endothelial cell isolates |
| US20100292303A1 (en) | 2007-07-20 | 2010-11-18 | Birrer Michael J | Gene expression profile for predicting ovarian cancer patient survival |
| KR101720760B1 (ko) | 2008-01-25 | 2017-03-28 | 오르후스 우니베르시테트 | Ｉｇｆｂｐ-4에 대한 ｐａｐｐ-ａ 활성의 선택적 엑소사이트 억제 |
| WO2010020004A1 (en) * | 2008-08-22 | 2010-02-25 | Children's Medical Research Institute | Compositions and methods for inhibition of adipogenesis and the treatment of obesity |
-
2014
- 2014-05-12 WO PCT/DK2014/050131 patent/WO2014180485A2/en not_active Ceased
- 2014-05-12 MX MX2015015519A patent/MX2015015519A/es unknown
- 2014-05-12 JP JP2016512227A patent/JP2016520583A/ja active Pending
- 2014-05-12 EA EA201591894A patent/EA201591894A1/ru unknown
- 2014-05-12 HK HK16103840.8A patent/HK1215929A1/zh unknown
- 2014-05-12 US US14/889,997 patent/US20160151405A1/en not_active Abandoned
- 2014-05-12 CN CN201480031999.4A patent/CN105263510A/zh active Pending
- 2014-05-12 CA CA2911933A patent/CA2911933A1/en not_active Abandoned
- 2014-05-12 EP EP14730423.2A patent/EP2994158A2/en not_active Withdrawn
-
2019
- 2019-10-11 US US16/599,706 patent/US11318158B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fossmark et al. | Adverse effects of proton pump inhibitors—evidence and plausibility | |
| Uchiyama et al. | Proton pump inhibitors and oncologic treatment efficacy: a practical review of the literature for oncologists | |
| Rajabi et al. | The role of angiogenesis in cancer treatment | |
| Mercer et al. | Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF | |
| NZ584787A (en) | Inhibition of angiogenesis with a Bv8 antagonist | |
| JP2012019790A5 (enExample) | ||
| JP2015508063A5 (enExample) | ||
| UA113712C2 (xx) | Антитіло до fap і способи його застосування | |
| MX2011008799A (es) | Polipeptidos, dominios variables de anticuerpos, y antagonistas anti-tnfr1 mejorados. | |
| PH12016502345B1 (en) | Anti-gitr antibodies and methods of use thereof | |
| MY198928A (en) | B7-h3 antibody, antigen-binding fragment thereof and medical use thereof | |
| JP2018501197A5 (enExample) | ||
| FI3218406T4 (fi) | Cd73:lle spesifisiä sitojamolekyylejä ja niiden käyttöjä | |
| JP2016537383A5 (enExample) | ||
| EA202091810A1 (ru) | Антитела к b7-h4 и способы их применения | |
| JP2018052979A5 (enExample) | ||
| JP2017508475A5 (enExample) | ||
| JP2016169229A5 (enExample) | ||
| JP2017113019A5 (enExample) | ||
| JP2016512214A5 (enExample) | ||
| WO2017062496A3 (en) | Anti-sas1b antibodies, associated methods of use, and compositions and methods for detecting and treating cancer | |
| BR112018011390A2 (pt) | compostos de quinolina, método de preparação dos mesmos, e uso dos mesmos como fármaco inibidor de transportador de urato | |
| JP2017530372A5 (enExample) | ||
| Cai et al. | Cellular senescence in hepatocellular carcinoma: the passenger or the driver? | |
| BR112016007864A2 (pt) | método para a prognose e tratamento de metástase de câncer |